We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Combining Biomarkers Predicts Metastasis in Medullary Thyroid Carcinoma

By LabMedica International staff writers
Posted on 18 Mar 2020
Medullary thyroid carcinoma (MTC) is a neuroendocrine neoplasm originating from thyroid parafollicular C cells and accounts for only 5% of all thyroid cancers, but its malignancy is relatively high, causing 8% to 13% of thyroid cancer‐related deaths due to its aggressiveness.

It has been reported that MTC can synthesize and secrete a variety of bioactive substances, such as calcitonin (Ctn), carcinoembryonic antigen (CEA), and neuron‐specific enolase (NSE). More...
Numerous reports have shown that the expression levels of Ctn and CEA are related to cervical lymph node metastasis,

Clinical Laboratory Scientists at the Sir Run Run Shaw Hospital (Hangzhou, China) enrolled 74 consecutive patients (39 males and 35 females, mean age 51.4 ± 12.9 years) who underwent surgery for untreated MTC, from January 2013 to April 2019. Fasting blood samples were drawn from all patients before surgery in the morning and transported to the laboratory within three hours after phlebotomizing. Cervical lymph node dissection was performed during thyroidectomy.

Serum Ctn was measured via Siemens IMMULITE 2000 automatic chemiluminescence immunoassay analyzer (Siemens Healthcare Diagnostics Ltd, Erlangen Germany); serum alpha‐fetoprotein (AFP), carbohydrate‐associated antigen 19‐9 (CA19‐9), and CEA were measured by Siemens Centaur XP automatic chemiluminescence immunoassay analyzer; serum cytokeratin 19 fragment (CYFRA21‐1) and NSE were measured by Roche Cobas e 602 automatic electrochemical luminescence immunoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany). Immunohistochemistry was used to make the diagnosis of MTC, if the case was difficult to determine by routine pathology techniques.

The scientists reported that the rate of lateral lymph node metastasis (LLNM) in their study was 48.64% (36/74). The expression levels of serum Ctn, CEA, and NSE in MTC with LLNM were significantly higher than those without LLNM; however, there was no significant difference in the levels of serum AFP, CYFRA21‐1, CA19‐9, and CA242 between the two groups.

The area under the curve (AUC) predicted by serum Ctn, CEA, and NSE for LLNM in MTC patients was 0.867, 0.831, and 0.726, respectively, and the AUC of serum Ctn, CEA, and NSE combined detection was up to 0.89, higher than using a single biomarker. The sensitivity and specificity of serum Ctn, CEA, and NSE combined detection in prediction of LLNM were 88.9% and 81.6%, respectively.

The authors concluded that the concentrations of serum Ctn, CEA, and NSE are closely related to LLNM in MTC, and the combined detection of all three biomarkers has a higher clinical value in the evaluation of MTC patients with LLNM. The study was published on March 6, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Sir Run Run Shaw Hospital
Siemens Healthcare Diagnostics
Roche Diagnostics



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The SimpleScreen CRC platform uses multiomics, AI, and machine learning to analyze blood-based signals and detect cancer-associated patterns (Photo courtesy of Freenome)

Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions

Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.